May 5, 2021 7:00 am EDT New Data Demonstrate that 99% of Surveyed Patients Diagnosed With Uveal Melanoma Gain Value From DecisionDx-UM Test
May 4, 2021 7:00 am EDT Castle Biosciences Collaborates With the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.
Apr 30, 2021 7:00 am EDT Castle Biosciences Supports American Academy of Dermatology's "Skin Cancer, Take a Hike!™" Steps Challenge for Skin Cancer Awareness Month
Apr 27, 2021 7:05 am EDT Castle Biosciences Signs Definitive Agreement to Acquire Myriad myPath® Laboratory
Apr 26, 2021 7:00 am EDT Castle Biosciences to Release First Quarter 2021 Financial Results, Provide Pipeline Update and Host Conference Call on Monday, May 10, 2021
Apr 23, 2021 7:00 am EDT Castle Biosciences Presents Data Demonstrating DecisionDx-Melanoma as Significant, Independent Predictor of Recurrence in Stage I Cutaneous Melanoma Population
Apr 22, 2021 7:00 am EDT Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention
Apr 16, 2021 7:00 am EDT Castle Biosciences Presents Data at the 10th World Congress of Melanoma and 17th European Association of Dermato-Oncology Congress
Apr 15, 2021 7:00 am EDT Late-Breaking New Independent Validation Study of 1,674 Patients Demonstrates Castle Biosciences' i31-GEP Artificial Intelligence Algorithm Improves Precision of Sentinel Lymph Node Positivity Prediction in Cutaneous Melanoma
Apr 14, 2021 7:00 am EDT Largest, Independent, Prospective Study Demonstrates Utility of DecisionDx®-Melanoma for Prediction of Outcomes in Patients With Cutaneous Melanoma Referred for Sentinel Node Biopsy
